United States

Circassia Pharmaceuticals PLC (CIRCI.L)

CIRCI.L on London Stock Exchange

28 Apr 2017
Change (% chg)

0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Circassia Pharmaceuticals fy revenues increased to 23.1 mln stg
Tuesday, 25 Apr 2017 02:00am EDT 

April 25 (Reuters) - Circassia Pharmaceuticals Plc ::Preliminary results for year ended 31 December 2016.FY revenues increased to £23.1 million (2015: £10.8 million).FY research and development investment £46.2 million (2015: £46.8 million) including allergy expenditure of £21.5 million.FY underlying loss for year £57.4 million (2015: £50.0 million); total loss £137.4 million (2015: £50.0 million).Fy allergy portfolio provisions, restructuring costs and impairments £80.0 million 4 (2015: £nil).Strong balance sheet with £117.4 million cash 5 at 31 december 2016 (31 december 2015: £203.8 million with £33.2 million relating to 2015 acquisitions paid during 2016).  Full Article

Circassia to secure certain U.S. commercial rights to Tudorza, Duaklir from AstraZeneca
Friday, 17 Mar 2017 03:00am EDT 

Circassia Pharmaceuticals Plc : Proposed collaboration and securing of certain U.S. Commercial rights to Tudorza And Duaklir from Astrazeneca . Deal for consideration of up to us$230 million . Deal includes US$50 million in ordinary shares plus future royalties based on Duaklir sales . Intends to fund deferred and contingent consideration through third-party financing . Circassia will make research and development contributions of up to US$62.5 million payable to Astrazeneca as deferred payments . Intends to fund research and development contributions through its returns from commercial collaboration and profit share with Astrazeneca .Deal anticipated to be earnings enhancing for Circassia after one year and broadly cash neutral for three years, then cash generative.  Full Article

Circassia Pharma says 80.47 pct shareholders at AGM vote to approve directors' pay report
Wednesday, 18 May 2016 12:28pm EDT 

Circassia Pharmaceuticals Plc :Says 80.47 percent shareholders present at AGM vote to approve directors' remuneration report; 19.53 percent against.  Full Article

Circassia Pharmaceuticals Plc completes acquisition of Prosonix Limited
Monday, 15 Jun 2015 08:19am EDT 

Circassia Pharmaceuticals Plc:Says the acquisition of Prosonix Limited has completed on June15.  Full Article

Circassia Pharma Plc announces issue of equity
Friday, 15 May 2015 02:04am EDT 

Circassia Pharmaceuticals PLC:Intention to raise about 275 mln Pounds (before expenses) through the issue of new ordinary shares of 0.08 pence each in the Company in conditional placing.The placing and open offer is being fully underwritten by J.P. Morgan Securities plc and Peel Hunt LLP on, and subject to, the terms of the placing agreement between the company, J.P. Morgan Cazenove and Peel Hunt.Circassia has also separately announced its intention to acquire the entire issued and to be issued share capital of Prosonix.Says for aggregate consideration of up to 100 mln Pounds to be paid in cash, of which 30 mln Pounds is contingent on UK approval of Prosonix's lead product, which is currently under review by the UK Medicines and Healthcare products Regulatory Agency ( MHRA).These proposed transactions are not interconditional, but are both conditional on approval of the placing.  Full Article

Circassia Pharma announces acquisition and placing of shares
Friday, 15 May 2015 02:00am EDT 

Circassia Pharmaceuticals Plc:Intends to make an all cash offer to acquire Aerocrine.For total consideration of up to 1.78 bln swedish crown (about 139 mln pounds).Also intends to acquire Prosonix for an aggregate cash consideration of up to 100 mln pounds.Proposes to raise 275 mln pounds, through a Placing and Open Offer.Proposes to use the net proceeds to fund the Acquisitions, Aerocrine's and Prosonix's future operational requirements within the Enlarged Group and to repay the Aerocrine Credit Agreement.  Full Article

More From Around the Web